Abstract
Tests with 52 strains of Staphylococcus aureus compared ceforanide and cefonicid. Addition of 50% human serum to the test system reduced the bacteriostatic and bactericidal activities of cefonicid, but ceforanide was not affected as greatly.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Actor P., Uri J. V., Zajac I., Guarini J. R., Phillips L., Pitkin D. H., Berges D. A., Dunn G. L., Hoover J. R., Weisbach J. A. SK&F 75073, new parenteral broad-spectrum cephalosporin with high and prolonged serum levels. Antimicrob Agents Chemother. 1978 May;13(5):784–790. doi: 10.1128/aac.13.5.784. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Barry A. L., Lasner R. A. In-vitro methods for determining minimal lethal concentrations of antimicrobial agents. Am J Clin Pathol. 1979 Jan;71(1):88–92. doi: 10.1093/ajcp/71.1.88. [DOI] [PubMed] [Google Scholar]
- Chambers H. F., Mills J., Drake T. A., Sande M. A. Failure of a once-daily regimen of cefonicid for treatment of endocarditis due to Staphylococcus aureus. Rev Infect Dis. 1984 Nov-Dec;6 (Suppl 4):S870–S874. doi: 10.1093/clinids/6.supplement_4.s870. [DOI] [PubMed] [Google Scholar]
- Greenman R. L., Arcey S. M., Gutterman D. A., Zweig R. M. Twice-daily intramuscular ceforanide therapy of Staphylococcus aureus endocarditis in parenteral drug abusers. Antimicrob Agents Chemother. 1984 Jan;25(1):16–19. doi: 10.1128/aac.25.1.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jones R. N., Thornsberry C., Barry A. L., Fuchs P. C., Gavin T. L., Gerlach E. H. BL-S786, a new parenteral cephalosporin. II. In vitro antimicrobial activity comparison with six related cephalosporins. J Antibiot (Tokyo) 1977 Jul;30(7):583–592. doi: 10.7164/antibiotics.30.583. [DOI] [PubMed] [Google Scholar]
- Kunkel M. J., Iannini P. B. Cefonicid in a once-daily regimen for treatment of osteomyelitis in an ambulatory setting. Rev Infect Dis. 1984 Nov-Dec;6 (Suppl 4):S865–S869. doi: 10.1093/clinids/6.supplement_4.s865. [DOI] [PubMed] [Google Scholar]
- Nightingale C. H., Quintiliani R., Dudley M. N., Gough P., Hickingbotham M., Jordan N. S., Rose D., Toscani M. Tissue penetration and half-life of cefonicid. Rev Infect Dis. 1984 Nov-Dec;6 (Suppl 4):S821–S828. doi: 10.1093/clinids/6.supplement_4.s821. [DOI] [PubMed] [Google Scholar]
- Platt R., Rosner B. Effect of hydrogen ion and protein concentrations on the activity of beta-lactam antibiotics. Rev Infect Dis. 1984 Nov-Dec;6 (Suppl 4):S829–S834. doi: 10.1093/clinids/6.supplement_4.s829. [DOI] [PubMed] [Google Scholar]
- Sahm D. F., Baker C. N., Jones R. N., Thornsberry C. Influence of growth medium on the in vitro activities of second- and third-generation cephalosporins against Streptococcus faecalis. J Clin Microbiol. 1984 Sep;20(3):561–567. doi: 10.1128/jcm.20.3.561-567.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Shanholtzer C. J., Peterson L. R., Mohn M. L., Moody J. A., Gerding D. N. MBCs for Staphylococcus aureus as determined by macrodilution and microdilution techniques. Antimicrob Agents Chemother. 1984 Aug;26(2):214–219. doi: 10.1128/aac.26.2.214. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Slutkin G., Marzouk J., Dall L., Mills J. Comparison of cefonicid and cefazolin for treatment of soft-tissue infections. Rev Infect Dis. 1984 Nov-Dec;6 (Suppl 4):S853–S856. doi: 10.1093/clinids/6.supplement_4.s853. [DOI] [PubMed] [Google Scholar]
- Smyth R. D., Pfeffer M., Glick A., Van Harken D. R., Hottendorf G. H. Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin. Antimicrob Agents Chemother. 1979 Nov;16(5):615–621. doi: 10.1128/aac.16.5.615. [DOI] [PMC free article] [PubMed] [Google Scholar]